About StemCyte

It is not just saving cord blood.

It is about Saving Lives.

StemCyte is dedicated to expanding the applications of cell therapy to address currently incurable diseases, paving the way for a healthier future through its guiding principle: “Better Cell, Better Life.”

Founded in the United States in 1997, StemCyte has established a strong presence in Taiwan and India. To date, it has built a public cord blood bank with over 36,000 units, making it the largest in scale globally, with unparalleled racial diversity and superior quality. StemCyte is also among the few biotechnology companies that operate both public and private cord blood banks.

Over the past 20 years, StemCyte has provided more than 2,300 cord blood units to over 350 transplant centers worldwide, supporting the treatment of various diseases. In November 2024, StemCyte became the first private company in the world to obtain FDA approval for a cord blood biologics license. Moving forward, StemCyte will continue its commitment to advancing the development of cord blood cell therapies, ensuring that physicians and patients around the globe have access to safe and effective cell therapy resources.

R&D Team & Cell Therapy Solutions.

StemCyte has a professional management and R&D team across Taiwan and the United States, with core capabilities in new drug development, manufacturing, clinical trials, and international sales.

StemCyte collaborates with international medical centers such as City of Hope in the United States, Taipei Medical University Hospital, and Tzu Chi Hospital to conduct multiple human clinical trials, including long-Covid, spinal injury, acute stroke, cerebral palsy, and cancer immunotherapy.

20 years of unremitting efforts

StemCyte upholds the highest standards and has achieved international certifications from AABB and FACT in both the US and Taiwan, providing high-quality and high-activity cell therapy products.

Since 2012, StemCyte US has collaborated with the California government and the UC Davis to implement the “Umbilical Cord Blood Collection Program (UCBCP)”, providing cord blood for transplantation and research to the California government, making it one of the few private companies trusted by the US government for such collaborations.

Scroll to Top